Displaying 201 - 220 of 4571
FTC Announces 2024 Jurisdictional Threshold Updates for Interlocking Directorates
Date
The Federal Trade Commission has approved revised jurisdictional thresholds for Section 8 of the Clayton Act, which prohibits interlocking directorates. For 2024, thresholds under Section 8 of the Act...
Syngenta and Corteva, FTC v.
The Federal Trade Commission and state partners have filed a complaint in federal court alleging that pesticide manufacturers Syngenta Crop Protection and Corteva, Inc. have used so-called “loyalty” programs to block and restrict generic competition from pesticide markets, leaving farmers to pay elevated prices for crop protection. The complaint seeks to bar Syngenta and Corteva from continuing these programs and from entering into any similar arrangements in the future, and to restore competition to affected markets.
Type of Action
Federal
Last Updated
FTC Matter/File Number
191 0031
Case Status
Pending
FTC Publishes Inflation-Adjusted Civil Penalty Amounts for 2024
Date
The Federal Trade Commission has adjusted the maximum civil penalty dollar amounts for violations of 16 provisions of law the FTC enforces, as required by the Federal Civil Penalties Inflation...
FTC to Host Virtual Summit on Artificial Intelligence
Date
The Federal Trade Commission’s Office of Technology is hosting a virtual tech summit on January 25, 2024 that will bring together a diverse group of stakeholders to discuss key developments in the...
Statement on FTC Win Securing Temporary Block of IQVIA’s Acquisition of Propel Media
Date
The U.S. District Court for the Southern District of New York granted on December 29, 2023, the Federal Trade Commission’s request for a preliminary injunction to prevent IQVIA Holdings Inc. (IQVIA)...
FTC, DOJ Issue Fiscal Year 2022 Hart-Scott-Rodino Notification Report
Date
The Federal Trade Commission, together with the Justice Department’s Antitrust Division, released their annual report detailing fiscal year 2022 data on the HSR Premerger Notification Program, which...
John Muir Health/Tenet Healthcare Co., In the Matter of
The Federal Trade Commission sued to block John Muir Health’s proposed $142.5 million deal to acquire sole ownership of San Ramon Regional Medical Center, LLC from current majority owner Tenet Healthcare Corporation, saying the deal will drive up health care costs.
The Commission issued an administrative complaint and authorized a lawsuit in federal court alleging the proposed acquisition will eliminate head-to-head competition between John Muir Health and nearby San Ramon Regional Medical Center.
On December 18, 2023 the FTC and California moved to dismiss their federal court case and the FTC dismissed its administrative challenge following John Muir announcing it would terminate its proposed deal to acquire Tenet’s remaining interest in San Ramon Medical Center.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2310054
Docket Number
9421
Case Status
Closed
Statement of Chair Lina M. Khan Joined by Commissioner Rebecca Kelly Slaughter In the Matter of Sanofi/Maze Therapeutics
Date
By
Lina M. Khan, Chair;
Rebecca Kelly Slaughter, Commissioner
Matter Number
D09422
File
Text of Statement
(126.92 KB)
Sanofi/Maze Therapeutics, Inc., In the Matter of
On December 13, 2023, the FTC moved to dismiss its case challenging the transaction following Sanofi’s decision to terminate its transaction with Maze Therapeutics Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
2310091
Docket Number
9422
Case Status
Closed
FTC Staff Report Details Key Takeaways from AI and Creative Fields Panel Discussion
Date
In a new report, Federal Trade Commission staff detailed key takeaways from an October 2023 public virtual roundtable that examined how generative artificial intelligence, tools that can generate...
Statement Regarding the Termination of John Muir’s Takeover of San Ramon Regional Medical Center from Tenet Healthcare
Date
The FTC and the State of California moved to dismiss their case challenging John Muir Health’s proposed deal to acquire sole ownership of San Ramon Regional Medical Center, LLC from current majority...
Statement Regarding Illumina’s Decision to Divest Grail
Date
Illumina, Inc. announced it would divest Grail, Inc. following a U.S. Court of Appeals for the Fifth Circuit decision that supported the Federal Trade Commission’s determination that the acquisition...
Federal Trade Commission and Justice Department Release 2023 Merger Guidelines
Date
Today, the Federal Trade Commission and the Justice Department jointly issued the 2023 Merger Guidelines, which describe factors and frameworks the agencies utilize when reviewing mergers and...
FTC Approves Final Order Settling Horizon Therapeutics Acquisition Challenge
Date
The Federal Trade Commission today finalized a consent order that resolves potential competitive harm stemming from Amgen Inc.’s acquisition of Horizon Therapeutics plc. As part of a nationwide...
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
231 0037
Docket Number
9414
Case Status
Closed
Displaying 201 - 220 of 4571